Press release Thursday 25 July 22.01 CET
Webcast & teleconference Friday 26 July 14.00 CET
Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.
Onno's view on the collaboration with Gilead.
This is the Galapagos way of working.
We are conducting clinical trials in several inflammatory indications, cystic fibrosis, fibrosis and osteoarthritis.